Aromatase inhibitors: potential reproductive implications.
MEDLINE, EMBASE, Scopus, and Web of Science databases literature search from inception to March 2009 was performed to identify published clinical trials and cohort, observational, and in vitro studies that evaluated the use of aromatase inhibitors in reproductive medicine for indications other than ovulation induction. Aromatase inhibitors are currently being investigated for breast cancer prevention in women at high risk. Aromatase inhibitors may be used for treatment of symptomatic myomas and endometriosis as an alternative to surgical intervention. Current evidence does not support the routine use of aromatase inhibitors for these conditions without prospective controlled trials. Aromatase inhibitor cotreatment can be used to prevent the initial estrogen flare effect of gonadotropin-releasing hormone agonist treatment to offer flexibility in initiating this therapy.
Bedaiwy
Mohamed A
MA
University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Mousa
Noha A
NA
Casper
Robert F
RF
D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000503:physiopathology / Q000517:prevention & control; D003131:Combined Modality Therapy; D004967:Estrogens / Q000502:physiology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy / Q000601:surgery; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000601:surgery
D047072:Aromatase Inhibitors; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone